<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04231006</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-218-19</org_study_id>
    <nct_id>NCT04231006</nct_id>
  </id_info>
  <brief_title>Salvage HDR for Locally Recurrent Prostate Cancer</brief_title>
  <acronym>PROSALBRA</acronym>
  <official_title>Salvage High Dose Rate Brachytherapy for Local Recurrence in Prostate Cancer: A Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study offers focal salvage brachytherapy for prostate cancer patients with a local&#xD;
      recurrence after primary defintive radiotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to examine the efficacy and toxicity of focal salvage high dose rate&#xD;
      brachytherapy (HDR BT) for patients with locally recurrent prostate cancer after definitive&#xD;
      external beam radiotherapy. Furthermore, the investigators want to assess, whether it is&#xD;
      feasible to perform salvage HDR BT as a focal treatment based on multiparametric (mp) pelvine&#xD;
      MRI and PSMA PET/CT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2035</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to castration-resistant prostate cancer</measure>
    <time_frame>10 years</time_frame>
    <description>The time from intervention until the prostate cancer becomes castration resistant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Erectile dysfunction</measure>
    <time_frame>5 years</time_frame>
    <description>Erectile dysfunction as reported by patients in CTCAE PRO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary symptoms</measure>
    <time_frame>5 years</time_frame>
    <description>Urinary symptoms as reported by patients in CTCAE PRO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel symptoms</measure>
    <time_frame>5 years</time_frame>
    <description>Bowel symptoms as reported by patients in CTCAE PRO</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>High dose rate brachytherapy</intervention_name>
    <description>High dose rate brachytherapy will be delivered to the site of recurrence within the prostate gland based on MRI and PSMA PET/CT</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man ≥ 18 years, who had definitive EBRT or BT for prostate cancer T1-3b, N0-1, M0&#xD;
&#xD;
          -  ≥ 2 years since the end of primary radiotherapy&#xD;
&#xD;
          -  PSA recurrence Phoenix criteria (nadir + 2)&#xD;
&#xD;
          -  No evidence of regional lymph nodes or distant metastases on PSMA PET/CT&#xD;
&#xD;
          -  MRI guided biopsy-proven local recurrence of adenocarcinoma in the prostate gland or&#xD;
             seminal vesicles&#xD;
&#xD;
          -  GTV identifiable on mpMRI&#xD;
&#xD;
          -  No current endocrine therapy&#xD;
&#xD;
          -  Plasma testosterone ≥1.75 nm/l&#xD;
&#xD;
          -  PSA doubling time ≥ 6 months and ≤ 24 months&#xD;
&#xD;
          -  Performance status 0-1&#xD;
&#xD;
          -  DAN PSS score ≤ 20&#xD;
&#xD;
          -  Maximal urinary flow ≥ 10 ml/s&#xD;
&#xD;
          -  Life expectancy &gt; 5 years&#xD;
&#xD;
          -  PSA ≤ 10 ug/L at recurrence&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pubic arc interference or major calcifications within the prostate gland.&#xD;
&#xD;
          -  Contraindication for spinal or general anaesthesia.&#xD;
&#xD;
          -  Conditions indicating that the patient cannot go through the radiation therapy or&#xD;
             follow-up, or a condition where the treating oncologist thinks the patient should not&#xD;
             participate in the trial, for example due to language problems.&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Contraindications to 3T MRI&#xD;
&#xD;
          -  eGFR &lt; 30 ml/min&#xD;
&#xD;
          -  ≥ Gr 3 urinary toxicity at baseline as assessed by CTCAE 4&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Simon Buus, MD</last_name>
    <phone>+4540465291</phone>
    <email>simbuu@rm.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Oncology</name>
      <address>
        <city>Aarhus</city>
        <state>Region Midt</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Buus</last_name>
      <phone>40465291</phone>
      <email>simbuu@rm.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Simon Buus</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

